# Completeness Review: AIRemotePatientMonitoring

- **Review date:** 2026-07-18
- **Assessment basis:** Static source and configuration inspection only. Dependencies were not installed, and no build, database migration, external integration, or runtime workflow was executed.

## Classification

**Functional but incomplete**

## Verdict

This is a substantive but unfinished clinical/health application: 99 project-owned source files and 2 manifest(s) expose a coherent surface, but the source does not demonstrate a production-complete AIRemote Patient Monitoring workflow.

## Why it is not complete

- 28 files are explicitly named as gap/backlog surfaces, so page and route counts overstate implemented product capability.
- 23 project-owned files contain direct provider/chat-completion markers; generic model calls are not a substitute for typed domain tools, grounded evidence, deterministic rules, or evaluations.
- 34 files contain mock, sample, placeholder, simulated, or random-data signals, leaving important outcomes disconnected from authoritative systems.
- No explicit schema or migration evidence was found for durable, versioned domain state.
- No recognizable project-owned automated tests were found for the primary workflow.
- No checked-in CI workflow was found to continuously verify builds, tests, migrations, and security checks.
- No environment example/template was found, leaving required configuration and secret boundaries undocumented.

## Needed features

1. Implement the Remote Patient Monitoring care workflow with validated observations, decisions, ownership, follow-up, and clinician-visible uncertainty.
2. Connect authoritative EHR/FHIR, laboratory/imaging, device, pharmacy, scheduling, or payer systems appropriate to the workflow, with consent and failure handling.
3. Validate clinical accuracy, calibration, contraindications, missing-data behavior, bias, and escalation on versioned representative datasets.
4. Require clinician approval, least-privilege access, consent, immutable audit, retention controls, and a clearly documented non-diagnostic boundary.
5. Replace the generated “medication refill automation pharmacy int” gap surface with durable domain state, real integration behavior, explicit failure handling, and acceptance tests.
6. Add contract, integration, authorization, migration, failure-path, and end-to-end tests in CI, plus a documented nondestructive deployment/run path.

## Risks or launch blockers

- Incorrect or unreviewed output can cause patient harm.
- Health data requires strong privacy, access, retention, and audit controls.
- The root launcher can terminate unrelated processes occupying configured ports.
- The root launcher seeds, creates, migrates, or otherwise mutates database state during startup.
- The root launcher installs dependencies at run time, reducing reproducibility and expanding supply-chain risk.

## Evidence inspected

- `backend/package.json` — inspected project-owned structure or implementation evidence.
- `backend/src/server.js` — inspected project-owned structure or implementation evidence.
- `backend/src/routes/gap-no-anomaly-detection-on-vitals-stream.js` — inspected project-owned structure or implementation evidence.
- `start.sh` — inspected project-owned structure or implementation evidence.
- `backend/src/config/database.js` — inspected project-owned structure or implementation evidence.
- `backend/package-lock.json` — inspected project-owned structure or implementation evidence.

## Recommended next action

Choose one production clinical/health journey, connect its authoritative systems, define measurable acceptance tests, and close its data, permission, failure, and operational gaps before adding screens.

## Implementation progress (2026-07-18)

1. Implemented a governed non-diagnostic monitoring contract with timestamped/unit-bearing observations, device calibration/version, uncertainty, ownership, follow-up, reviewed refill proposals, and clinician-visible disposition.
2. Added typed fail-closed EHR/FHIR, laboratory, device, pharmacy, scheduling, payer, and secure-messaging adapters with consent, approval, idempotency, leased claims, retries, receipts, and dead letters.
3. Added validation evidence fields and acceptance rules for calibration, contraindications, missing data, representative cohorts/bias, accuracy, latency, and false-negative escalation.
4. Added signed tenant/role claims, least-privilege registration, consent/retention, independent clinician approval, immutable audit, receipt-backed erasure, and explicit bans on autonomous diagnosis, treatment, refill transmission, and emergency triage.
5. Quarantined the generated refill/decompensation and legacy direct-AI surfaces; the governed workflow records durable proposal, review, transmission prohibition, provider failure, and recovery state.
6. Added the additive migration, removed startup schema/seed mutation, fail-closed auth/database configuration, read-only CI, safe `start.sh`, `.env.example`, and `OPERATIONS.md`. The focused suite passes 10/10 locally; no EHR/device/pharmacy integration, clinical deployment, patient use, or regulated validation is claimed.
